Approval of Financial results of Quarter ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma reported a net loss of Rs 76.45 lakhs for Q1 FY26 (quarter ended June 30, 2025), compared to a marginal profit of Rs 1.23 lakhs in the same quarter last year. Revenue from operations collapsed sharply by about 75% to Rs 1.94 crores from Rs 7.82 crores year-on-year. Finance costs more than doubled to Rs 28.01 lakhs, while the full-year FY25 had ended with a loss of Rs 2.09 crores (after booking an exceptional item of Rs 1.07 crores). The statutory auditor's limited review report flags a caveat around 'non usage of assets.' Separately, the Board appointed Mr. Samsad Alam Khan as Secretarial Auditor for a five-year term (FY26–FY30), subject to shareholder approval.
The steep ~75% revenue drop, a return to losses, and rising finance costs point to significant business stress for shareholders, likely weighing on the stock price and raising questions about the company's operational viability.